Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial...
175 insider sale filings on record · latest filing 2026-10-05.
No open-market insider purchases (SEC Form 4 code P) on record for BLTE.